Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches. 2021

Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Cervical cancer, caused by human papillomavirus (HPV), is the fourth most common type of cancer among women worldwide. While HPV prophylactic vaccines are available, they have no therapeutic effects and do not clear up existing infections. This study aims to design a therapeutic vaccine against cervical cancer using reverse vaccinology. In this study, the E6 and E7 oncoproteins from HPV16 were chosen as the target antigens for epitope prediction. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) epitopes were predicted, and the best epitopes were selected based on antigenicity, allergenicity, and toxicity. The final vaccine construct was composed of the selected epitopes, along with the appropriate adjuvant and linkers. The multi-epitope vaccine was evaluated in terms of physicochemical properties, antigenicity, and allergenicity. The tertiary structure of the vaccine construct was predicted. Furthermore, several analyses were also carried out, including molecular docking, molecular dynamics (MD) simulation, and in silico cloning of the vaccine construct. The results showed that the final proposed vaccine could be considered an effective therapeutic vaccine for HPV; however, in vitro and in vivo experiments are required to validate the efficacy of this vaccine candidate.

UI MeSH Term Description Entries
D009856 Oncogene Proteins, Viral Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities. Viral Oncogene Proteins,Viral Transforming Proteins,v-onc Proteins,Transforming Proteins, Viral,v onc Proteins
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006377 T-Lymphocytes, Helper-Inducer Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions. Helper Cell,Helper Cells,Helper T Cell,Helper-Inducer T-Lymphocytes,Inducer Cell,Inducer Cells,T-Cells, Helper-Inducer,T-Lymphocytes, Helper,T-Lymphocytes, Inducer,Helper T-Cells,Cell, Helper T,Cells, Helper T,Helper Inducer T Lymphocytes,Helper T Cells,Helper T-Cell,Helper T-Lymphocyte,Helper T-Lymphocytes,Helper-Inducer T-Cell,Helper-Inducer T-Cells,Helper-Inducer T-Lymphocyte,Inducer T-Lymphocyte,Inducer T-Lymphocytes,T Cell, Helper,T Cells, Helper,T Cells, Helper Inducer,T Lymphocytes, Helper,T Lymphocytes, Helper Inducer,T Lymphocytes, Inducer,T-Cell, Helper,T-Cell, Helper-Inducer,T-Cells, Helper,T-Lymphocyte, Helper,T-Lymphocyte, Helper-Inducer,T-Lymphocyte, Inducer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071497 Immunogenicity, Vaccine The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses. It is typically measured in vaccinated individuals in observational studies setting. Antigenicity, Vaccine,Vaccine Antigenicity,Vaccine Immunogenicity
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D050725 Papillomavirus E7 Proteins ONCOGENE PROTEINS from papillomavirus that deregulate the CELL CYCLE of infected cells and lead to NEOPLASTIC CELL TRANSFORMATION. Papillomavirus E7 proteins have been shown to interact with various regulators of the cell cycle including RETINOBLASTOMA PROTEIN and certain cyclin-dependent kinase inhibitors. E7 Oncogene Proteins,Oncogene Protein E7, Papillomavirus,E7 Proteins, Papillomavirus,Oncogene Proteins, E7

Related Publications

Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
September 2023, Journal of biomolecular structure & dynamics,
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
January 2024, Journal of fungi (Basel, Switzerland),
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
April 2018, Vaccine,
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
January 2021, International journal of peptide research and therapeutics,
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
December 2020, International journal of biological macromolecules,
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
January 2023, Frontiers in cellular and infection microbiology,
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
May 2024, International journal of biological macromolecules,
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
August 2023, Medical oncology (Northwood, London, England),
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
February 2023, Vaccines,
Samira Sanami, and Fatemeh Azadegan-Dehkordi, and Mahmoud Rafieian-Kopaei, and Majid Salehi, and Maryam Ghasemi-Dehnoo, and Mehran Mahooti, and Morteza Alizadeh, and Nader Bagheri
November 2022, Animal biotechnology,
Copied contents to your clipboard!